<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02208700</url>
  </required_header>
  <id_info>
    <org_study_id>1141459</org_study_id>
    <nct_id>NCT02208700</nct_id>
  </id_info>
  <brief_title>Efficacy of Oxepa Enteral Feeding in LTAC (Long Term Acute Care Hospital) Patients on Chronic Ventilation- a Pilot Study</brief_title>
  <acronym>ANUS1305</acronym>
  <official_title>Efficacy of the Use of Enteral Feeding High in EPA,GLA and Antioxidants in LTAC Patients on Chronic Ventilation- a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grace Hospital, Cleveland, Ohio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grace Hospital, Cleveland, Ohio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with mechanical ventilation have shown improved weaning rates when enteral tube
      feeding high in EPA, GLA and antioxidants were fed to patients in the critical care setting.

      LTAC Patients on chronic mechanical ventilation will have decreased days an mechanical
      ventilation, decreased mortality rates and decreased organ failure when fed an enteral
      product high in EPA, GLA and antioxidants compared to an isotonic high fiber enteral
      nutrition product.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of days on mechanical ventilation</measure>
    <time_frame>14 days from start of enteral feeding</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Lung Injury</condition>
  <condition>Mechanical Ventilation Complication</condition>
  <condition>Dietary Modification</condition>
  <arm_group>
    <arm_group_label>Oxepa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Other: Therapeutic nutrition with EPA, GLA and antioxidants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jevity 1.5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Other: Jevity 1.5 Complete Balanced Nutrition with Fiber .</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oxepa</intervention_name>
    <description>Therapeutic nutrition with EPA, GLA&lt; and antioxidants</description>
    <arm_group_label>Oxepa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Jevity 1.5</intervention_name>
    <description>Complete balanced nutrition with a unique fiber blend</description>
    <arm_group_label>Jevity 1.5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        &gt;18 years old with Respiratory failure on mechanical ventilation with failure to wean
        Diagnosis of ARDS (Acute respiratory Distress Syndrome) Bilateral infiltrates -

        Exclusion Criteria:

        History Of pulmonary fibrosis, Terminal illness/ malignancies, &lt;28 day life expectancy,
        Hemodialysis, Active bleeding or bleeding disorder: DIC ( Disseminated intravascular
        Coagulation), Sickle Cell Anemia, Hemophilia Hemorrhagic or ischemic stroke, Liver failure,
        Head trauma with Glasgow coma scale score of &lt;5, Immunosuppression: WBC(White Blood Cell
        Count) &lt;5000, HIV positive, use of immunosuppressant drugs, Pregnancy, and Heart Failure
        with EF(Ejection Fraction) &lt;35%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Basma Ricaurte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grace Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grace Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Gorbach-Melchioris, MEd, RDNLD</last_name>
      <phone>216-476-2704</phone>
      <email>cgorbach-melchhioris@gracehospital.org</email>
    </contact>
    <investigator>
      <last_name>Basma Ricaurte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2014</study_first_submitted>
  <study_first_submitted_qc>August 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2014</study_first_posted>
  <last_update_submitted>August 1, 2014</last_update_submitted>
  <last_update_submitted_qc>August 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

